Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Bibliografische gegevens
Hoofdauteurs:	Moran, A, Ramakrishnan, S, Borg, C, Connolly, C, Couillard, S, Mwasuku, C, Pavord, I, Hinks, T, Lehtimaki, L
Formaat:	Conference item
Taal:	English
Gepubliceerd in:	European Respiratory Society 2020

Gelijkaardige items

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
door: Moran, AM, et al.
Gepubliceerd in: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
door: Shrimanker, R, et al.
Gepubliceerd in: (2017)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
door: Charlene Desaintjean, et al.
Gepubliceerd in: (2024-03-01)

Glucocorticoids and mepolizumab in eosinophilic asthma.
door: Bel, E, et al.
Gepubliceerd in: (2014)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
door: Andrea Portacci, et al.
Gepubliceerd in: (2023-10-01)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
door: Bel, E, et al.
Gepubliceerd in: (2014)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
door: S. K. Zyryanov, et al.
Gepubliceerd in: (2020-12-01)

Mepolizumab in refractory eosinophilic asthma.
door: Pavord, I, et al.
Gepubliceerd in: (2010)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
door: Arian Ghassemian, et al.
Gepubliceerd in: (2021-01-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
door: Pavord, I
Gepubliceerd in: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
door: Haldar, P, et al.
Gepubliceerd in: (2009)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
door: Howell, I, et al.
Gepubliceerd in: (2024)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
door: Erminia Ridolo, et al.
Gepubliceerd in: (2020-10-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
door: Kayser MZ, et al.
Gepubliceerd in: (2021-07-01)

Mepolizumab treatment in patients with severe eosinophilic asthma.
door: Ortega, H, et al.
Gepubliceerd in: (2014)

Mepolizumab for eosinophilic COPD
door: Sciurba, F, et al.
Gepubliceerd in: (2018)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
door: Osamu Matsuno, et al.
Gepubliceerd in: (2019-01-01)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
door: Yancey, S, et al.
Gepubliceerd in: (2016)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
door: Menzella F, et al.
Gepubliceerd in: (2016-06-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
door: Mirhojjat Khorasanizadeh, et al.
Gepubliceerd in: (2017-07-01)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
door: Gómez-Bastero Fernández A, et al.
Gepubliceerd in: (2022-05-01)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
door: Gunsoy, N, et al.
Gepubliceerd in: (2017)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
door: Laura J. Walsh, et al.
Gepubliceerd in: (2023-01-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
door: Alistair Cook, et al.
Gepubliceerd in: (2021-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
door: Howell, I, et al.
Gepubliceerd in: (2024)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
door: Imran Howell, et al.
Gepubliceerd in: (2024-07-01)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
door: Stephen G. Noorduyn, et al.
Gepubliceerd in: (2021-12-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
door: Francesco Menzella, et al.
Gepubliceerd in: (2016-12-01)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
door: Couillard, S, et al.
Gepubliceerd in: (2021)

Asthma in pregnancy: An update
door: Couillard, S, et al.
Gepubliceerd in: (2020)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
door: Shrimanker, R, et al.
Gepubliceerd in: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
door: Ortega, H, et al.
Gepubliceerd in: (2016)

Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort
door: Gittins, A, et al.
Gepubliceerd in: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
door: Steven W. Yancey, et al.
Gepubliceerd in: (2019-09-01)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
door: Lisha Li, et al.
Gepubliceerd in: (2021-06-01)

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
door: Kohei Somekawa, et al.
Gepubliceerd in: (2024-12-01)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
door: Andrew Menzies-Gow, et al.
Gepubliceerd in: (2019-09-01)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
door: Shrimanker, R, et al.
Gepubliceerd in: (2018)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
door: Oliver, ME, et al.
Gepubliceerd in: (2021)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
door: Carlos Martínez-Rivera, et al.
Gepubliceerd in: (2021-01-01)